Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors
by on Wednesday, May 9th, 2012 | No Comments
Condition: Neuroendocrine Tumors
Intervention: Drug: RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified May 2012
Originally posted here: Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors